BeiGene, Ltd. (NASDAQ:BGNE) PT Set at $52.00 by Maxim Group

  • BeiGene, Ltd. (NASDAQ:BGNE) PT Set at $52.00 by Maxim Group

BeiGene, Ltd. (NASDAQ:BGNE) PT Set at $52.00 by Maxim Group

Several analysts have released their opinion on BeiGene, Ltd. (NASDAQ:BGNE), with 3 analysts believing it is a strong buy. State of New Jersey Common Pension Fund D now owns 45,987 shares of the company's stock worth $1,684,000 after buying an additional 1,700 shares in the last quarter.

According to a report from research analyst Alethia Young of Credit Suisse, a PARP inhibitor may be on the horizon for Celgene. Renaissance Technologies LLC acquired a new position in BeiGene during the first quarter valued at about $238,000. Finally, Candriam Luxembourg S.C.A. purchased a new position in BeiGene during the first quarter worth about $4,210,000. The Clearbridge Investments Llc holds 1.11M shares with $132.11 million value, up from 1.10M last quarter. FMR LLC boosted its position in BeiGene by 2.8% in the first quarter. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Finally, Brown Advisory Inc. boosted its stake in Beigene by 30.2% in the fourth quarter.

ATR value of company was 2.16.

Investors are feeling more bearish on BeiGene, Ltd. - American Deposi lately if you take note of the uptick in short interest. (NASDAQ BGNE) traded up 26.80% during midday trading on Thursday, hitting $66.28. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.19. The stock's 50 day moving average is $40.06 and its 200 day moving average is $37.01.

Merck has been on a roll with the medicine, jumping to the front of the pack of companies with new immuno-oncology drugs, particularly after Keytruda extended survival as an initial treatment for advanced lung cancer, by far the largest oncology market.

Beigene Ltd (ADR) (NASDAQ:BGNE) stock reached a 1-year peak price of $54.47. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & global copyright & trademark laws. The original version of this story can be read at

A number of brokerages have commented on BGNE. William Blair reaffirmed an "outperform" rating on shares of BeiGene in a report on Thursday, June 1st. The overall volume in the last trading session was 2.3 Million shares. The stock of KeyCorp (NYSE:KEY) has "Buy" rating given on Monday, April 24 by Nomura. If the $50.49 price target is reached, the company will be worth $77.60 million more. Also, CEO John Oyler sold 98,500 shares of the business's stock in a transaction that occurred on Friday, June 23rd. About 211,606 shares traded or 129.76% up from the average. Following the sale, the chief executive officer now directly owns 88,535 shares of the company's stock, valued at $3,909,705.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Xiaodong Wang sold 35,000 shares of the company's stock in a transaction on Wednesday, June 28th.

The transfer of ownership could prove to be a win for the companies, helping Beigene establish a commercial presence ahead of the potential launch of its own portfolio, and giving Celgene a ticket out of direct responsibility for selling brand-name medicines in China, a growing challenge for big foreign drugmakers facing challenges to premium pricing there.